

The Cancer Research Institute funds research aimed at furthering the development of immunological approaches to the diagnosis, treatment, and prevention of cancer. The Institute's mission is to bring effective immune system-based therapies to cancer patients sooner.

To this end, CRI offers its Clinic and Laboratory Integration Program (CLIP) Grants to qualified scientists who are working to explore clinically relevant questions aimed at improving the effectiveness of cancer immunotherapies. The program supports pre-clinical and translational research that can be directly applied to optimizing cancer immunotherapy in the clinic.

OVERVIEW

The development of new and effective cancer treatment requires the translation of basic laboratory discoveries into novel therapies that can be tested in patients. This area of translational research—where laboratory findings move into clinical testing, and where questions from clinical studies are brought back into the lab—is critical to bringing new and better immunotherapies to patients.

The Cancer Research Institute established CLIP to support investigators who are studying critical topics at the intersection of laboratory and clinical research. CLIP grants provide up to \$200,000 over a two-year period.

PROGRAM UPDATE

CRI has obtained designated funding that will provide for a limited number of additional CLIP grants focused on topics related to biomarkers, including such topics as tumor mutational burden, microbiome, host genomic factors, and others. Proposals in this area are encouraged.

[View our funding directory](#) to see the types of research CLIP investigators are working on to change the face of cancer treatment.

[SEE APPLICATION GUIDELINES AND APPLY](#)

**Immunotherapy results may vary from patient to patient.*